Revolution Medicines files FDA NDA for daraxonrasib; FDA accepts 8-K filing
The company announced FDA acceptance for its first NDA for daraxonrasib and updated clinical progress in oncology.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day